MedTrace Logo

RUSSE / Russian Spiriva® Safety & Efficacy Study

NCT00613574 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 407

Last updated 2014-04-10

Study results available
· View outcomes & findings →

Summary

At the moment, there is hardly any structured safety and efficacy data collection on Tiotropium in Russia. Therefore, the objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety of Spiriva® (18 µg tiotropium inhalation capsules) delivered by HandiHaler®, in a national sample of Russian patients with varying severities of chronic obstructive pulmonary disease (COPD) in a real life setting over the 8 weeks.

Conditions

Interventions

DRUG

tiotropium-bromide

Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim Study Coordinator · BI Pharma Ges mbH Wien

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2007-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00613574 on ClinicalTrials.gov